The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the effectiveness of the of kallikrein in the different drug frequency for acute anterior circulation cerebral infarction.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huisheng Chen
• Treatments: Kallikreins

Criteria

Inclusion Criteria:

1. Age 18 to 80 years old;

2. First time diagnosed or have history of acute anterior circulation cerebral infarction without serious sequelae (mRS = 0-2);

3. Acute anterior circulation cerebral infarction with large artery atherosclerotic etiology;

4. Ability to randomize within 48 h of time last known free of new ischemic symptoms.

5. National Institute of Health stroke scale(NIHSS) ranges from 7 to 22;

6. signed written informed consent.

Exclusion Criteria:

1. Cerebral CT shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid hemorrhage, etc.;

2. Transient ischemic attack;

3. Serious disturbance of consciousness: Glasgow Coma ScaleGCS（GCS）≤8;

4. Combined angiotensin-converting enzyme inhibitor(ACEI) less than 5 half-time (according to its instruction), or need to be treated with ACEI;

5. Past or present suffering from hemorrhagic tendency of the disease;

6. The investigator in consideration of the other condition that the patients doesn't fit to participate in this clinical study.